WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H577233
CAS#: 122576-55-0
Description: Meteneprost potassium is a compound used as an early pregnancy terminator. It is a derivative of both PGE2 & PGF2alpha.
Hodoodo Cat#: H577233
Name: Meteneprost potassium
CAS#: 122576-55-0
Chemical Formula: C23H37KO4
Exact Mass: 416.23
Molecular Weight: 416.640
Elemental Analysis: C, 66.30; H, 8.95; K, 9.38; O, 15.36
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Meteneprost potassium
IUPAC/Chemical Name: Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-methylene-, monopotassium salt, (5Z,11alpha,13E,15R)-
InChi Key: AWJFDDHQLBRQDS-PWOMVKEHSA-M
InChi Code: InChI=1S/C23H38O4.K/c1-5-6-15-23(3,4)21(25)14-13-19-18(17(2)16-20(19)24)11-9-7-8-10-12-22(26)27;/h7,9,13-14,18-21,24-25H,2,5-6,8,10-12,15-16H2,1,3-4H3,(H,26,27);/q;+1/p-1/b9-7-,14-13+;/t18-,19+,20+,21+;/m0./s1
SMILES Code: [K+].CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(=O)[O-]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 416.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: A multicentre randomized comparative clinical trial of 200 mg RU486 (mifepristone) single dose followed by either 5 mg 9-methylene PGE(2) gel (meteneprost) or 600 microg oral PGE(1) (misoprostol) for termination of early pregnancy within 28 days of missed menstrual period. ICMR Task Force Study. Indian Council of Medical Research. Contraception. 2000 Sep;62(3):125-30. PubMed PMID: 11124359.
2: Kimball FA, Cornette JC, Bundy GL, Kirton KT. Plasma concentrations of 9-deoxo-16-dimethyl-9-methylene-PGE2 in rhesus monkeys after administration by various routes. Prostaglandins. 1980 Sep;20(3):559-69. PubMed PMID: 7422900.
3: Shapiro AG, Lasseter K, Cobiella A, Domenzain M. Intravaginal administration of 9-deoxo-9-methylene-16,16-dimethyl PGE2 for cervical dilation prior to suction curettage. Int J Gynaecol Obstet. 1982 Apr;20(2):137-40. PubMed PMID: 6125434.
4: Brenner PF, Marrs RP, Roy S, Mishell DR Jr. Termination of early gestation with 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2. Contraception. 1982 Sep;26(3):261-77. PubMed PMID: 6184197
